EC International NE 2265 SEC International NE 2265 SEC International NE 226



3EC International a.s., Hraničná 18, 821 05 Bratislava, Slovak Republic Notified body No. 2265

### **EU QUALITY MANAGEMENT SYSTEM CERTIFICATE**

No. 2023-IVDR/QS-001

#### TestLine Clinical Diagnostics s.r.o.

Registered place of business: Křižíkova 68, 612 00 Brno, Czech Republic

Manufacturing sites:

1. Křižíkova 68, 612 00 Brno, Czech Republic 2. Karásek 1767/1, 621 00 Brno, Czech Republic

SRN No.: CZ-MF-000001803

This EU Quality Management System Certificate issued in accordance with the Regulation (EU) 2017/746 of the European Parliament and of the Council on in vitro diagnostic medical devices as amended confirms, that quality management system of in vitro diagnostic medical device:

INFECTIOUS DISEASES, In vitro diagnostic devices which require knowledge regarding immunoassays (EMDN W0105 + IVP 3007) (detailed list is stated in Annex I)

Intended purpose: Annex II

**IVD MD class C** 

(detailed list is stated in the annex(es) if applicable)


meets the requirements on quality management system according to the Chapter I and III of Annex IX of the Regulation (EU) 2017/746 of the European Parliament and of the Council on in vitro diagnostic medical devices as amended.

Conditions for or limitations to the validity of the certificate: N/A

Validity of the certificate is conditional upon positive results of regular surveillance audits.

Notified body No. 2265 has performed assessment of the quality management system of the abovementioned in vitro diagnostic medical device and found that it meets the requirements stated above. The outcome of the assessment of the quality management system of the abovementioned in vitro diagnostic medical device is stated in the IVD MD Technical Documentation Assessment Report No. IVDR008\_2023 from 26.05.2023, IVD MD Performance Evaluation Assessment Report No. IVDR008\_2023 from 26.05.2023 and IVD MD Audit Report No. SK-0735-23 from 26.05.2023. Information on all examinations and tests performed is stated in the abovementioned reports and is available on request.

This **EU Quality Management System Certificate** applies only to the quality management system of the abovementioned in vitro diagnostic medical device. The certificate validity is conditional upon fulfilment of relevant legal requirements by the manufacturer.



Valid from: 06.06.2023 Valid until: 06.06.2028 First issue: 06.06.2023

Revision: 00 History: Annex III BEC INTERPRETARIA NB 2285

3EC International a.s. Ing. Katarina Tomin Srdošová, PhD. Ředitel NO2265

In Bratislava, Slovakia, 06.06.2023



### ANNEX I TO EU QUALITY MANAGEMENT SYSTEM CERTIFICATE No. 2023-IVDR/QS-001

issued for the company

### TestLine Clinical Diagnostics s.r.o.

Registered place of business: Křižíkova 68, 612 00 Brno, Czech Republic Manufacturing sites:

- 1. Křižíkova 68, 612 00 Brno, Czech Republic
- 2. Karásek 1767/1, 621 00 Brno, Czech Republic

List of in vitro diagnostic medical devices covered by the EU Quality Management System Certificate:

REF	Trade Name			
CMGMA48	Microblot-Array CMV IgG			
CMMMA48	Microblot-Array CMV IgM			
HSGMA48	Microblot-Array HSV 1+2 IgG			
HSMMA48	Microblot-Array HSV 1+2 IgM			
CL-PVG050	CLIA Parvovirus B19 IgG			
CL-PVM050	CLIA Parvovirus B19 IgM			

Page 1 of 3





Katarína Tomin Srdošová, PhD. Director of NB2265

In Bratislava, Slovakia, 06.06.2023 Valid until 06.06.2028



# ANNEX II TO EU QUALITY MANAGEMENT SYSTEM CERTIFICATE No. 2023-IVDR/QS-001

issued for the company

### TestLine Clinical Diagnostics s.r.o.

Registered place of business: Křižíkova 68, 612 00 Brno, Czech Republic

Manufacturing sites:

- 1. Křižíkova 68, 612 00 Brno, Czech Republic
- 2. Karásek 1767/1, 621 00 Brno, Czech Republic

Intended purpose of in vitro diagnostic medical devices covered by the EU Quality Management System Certificate:

Microblot-Array CMV IgG, ref. CMGMA48, Intended purpose: The Microblot-Array assay is intended for the diagnosis of CMV infection using IgG antibodies in human serum or plasma in the general population. The qualitative, semi-quantitative and quantitative automated assay is designed for professional use in a laboratory. The assay is not intended to assess the suitability for transfusion, transplantation or cell administration.

Microblot-Array CMV IgM, ref. CMMMA48, Intended purpose: The Microblot-Array assay is intended for the diagnosis of CMV infection using IgM antibodies in human serum or plasma in the general population. The qualitative, semi-quantitative and quantitative automated assay is designed for professional use in a laboratory. The assay is not intended to assess the suitability for transfusion, transplantation or cell administration.

**Microblot-Array HSV 1+2 IgG, ref. HSGMA48**, Intended purpose: The Microblot-Array assay is intended for the diagnosis of HSV infection using IgG antibodies in human serum or plasma in the general population. The qualitative, semi-quantitative and quantitative automated assay is designed for professional use in a laboratory.

**Microblot-Array HSV 1+2 IgM, ref. HSMMA48**, Intended purpose: The Microblot-Array assay is intended for the diagnosis of HSV infection using IgM antibodies in human serum or plasma in the general population. The qualitative, semi-quantitative and quantitative automated assay is designed for professional use in a laboratory.

**CLIA Parvovirus B19 IgG**, **ref. CL-PVG050**, Intended purpose: The chemiluminescence assay is intended for the diagnosis of parvovirus B19 infection using IgG antibodies in human serum or plasma in the general population. The quantitative automated assay is designed for professional use in a laboratory.

CLIA Parvovirus B19 IgM, ref. CL-PVM050, Intended purpose: The chemiluminescence assay is intended for the diagnosis of parvovirus B19 infection using IgM antibodies in human serum or plasma in the general population. The quantitative automated assay is designed for professional use in a laboratory.



Page 2 of 3

In Bratislava, Slovakia, 06.06.2023 Valid until 06.06.2028

nternetional NB 2266 SEC Internetional NE 2266

Katarina Tomin Srdošová, PhD. Director of NB2265



# ANNEX III TO EU QUALITY MANAGEMENT SYSTEM CERTIFICATE No. 2023-IVDR/QS-001

issued for the company

### TestLine Clinical Diagnostics s.r.o.

Registered place of business: Křižíkova 68, 612 00 Brno, Czech Republic Manufacturing sites:

- 1. Křižíkova 68, 612 00 Brno, Czech Republic
- 2. Karásek 1767/1, 621 00 Brno, Czech Republic

#### Certificate history:

Revision	EU QMS Certificate reference	Date of issue	Application for Conformity Assessment of IVD MD number	Description
00	2023-IVDR/QS-001	06.06.2023	IVDR008_2023 IVDR009_2023 IVDR010_2023	First issue

Page 3 of 3





Katarína Tomin Srdošová, PhD. Director of NB2265

In Bratislava, Slovakia, 06.06.2023 Valid until 06.06.2028

2265 SEC Informational NE 2265 SEC Informational NE 22